RECRUITING

Exercise Response in Humans With Obesity

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is being done to understand how chronic inflammation affects muscle function and responses to exercise.

Official Title

Exercise Response in Humans With Obesity

Quick Facts

Study Start:2023-09-22

Study Completion:2029-07

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05857150

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:20 Years to 45 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT

Inclusion Criteria	Exclusion Criteria
* Obese men and women ≥ 20 and ≤ 45 years of age.	* Diabetes or fasting plasma glucose \>126 mg/dL * Anemia (female subjects hemoglobin of \<11 g/dl and male subjects hemoglobin \<12 g/dl) * Active coronary artery disease or history of unstable macrovascular disease (unstable angina, myocardial infarction, stroke, and revascularization of coronary, peripheral or carotid artery within 3 months of recruitment) * Renal failure (serum creatinine \> 1.5mg/dl) * Chronic active liver disease defined as aspartate aminotransferase (AST)\>144 IU/L or alanine transaminase (ALT) \>165 IU/L) * Oral warfarin group medications or history of blood clotting disorders. * Smoking * Pregnancy or breastfeeding * Alcohol consumption greater than 2 glasses/day or other substance abuse * Untreated or uncontrolled hypothyroidism * Debilitating chronic disease (at the discretion of the investigators)

Inclusion Criteria

Exclusion Criteria

* Obese men and women ≥ 20 and ≤ 45 years of age.

* Diabetes or fasting plasma glucose \>126 mg/dL
* Anemia (female subjects hemoglobin of \<11 g/dl and male subjects hemoglobin \<12 g/dl)
* Active coronary artery disease or history of unstable macrovascular disease (unstable angina, myocardial infarction, stroke, and revascularization of coronary, peripheral or carotid artery within 3 months of recruitment)
* Renal failure (serum creatinine \> 1.5mg/dl)
* Chronic active liver disease defined as aspartate aminotransferase (AST)\>144 IU/L or alanine transaminase (ALT) \>165 IU/L)
* Oral warfarin group medications or history of blood clotting disorders.
* Smoking
* Pregnancy or breastfeeding
* Alcohol consumption greater than 2 glasses/day or other substance abuse
* Untreated or uncontrolled hypothyroidism
* Debilitating chronic disease (at the discretion of the investigators)

Contacts and Locations

Study Contact

Rachel Passehl

CONTACT

507-255-8112

Passehl.Rachel@mayo.edu

Principal Investigator

Ian Lanza, PhD

PRINCIPAL_INVESTIGATOR

Mayo Clinic

Study Locations (Sites)

Mayo Clinic in Rochester

Rochester, Minnesota, 55905

United States

Collaborators and Investigators

Sponsor: Mayo Clinic

Ian Lanza, PhD, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-09-22

Study Completion Date2029-07

Study Record Updates

Study Start Date2023-09-22

Study Completion Date2029-07

Terms related to this study

Additional Relevant MeSH Terms

Obese